{'fraction_non_alphanumeric': 0.016568047337278107, 'fraction_numerical': 0.0, 'mean_word_length': 5.934426229508197, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
PARACENTRAL ACUTE MIDDLE MACULOPATHY FOLLOWING ORAL INTAKE OF SUMATRIPTAN

We herein describe one patient with a recent history of sumatriptan intake, who presented with paracentral acute middle maculopathy diagnosed by optical coherence tomography and near-infrared imaging. To our knowledge, this is the first case-presentation of paracentral acute middle maculopathy after oral intake of sumatriptan. Purpose: The purpose of this report was to describe a case with paracentral acute middle maculopathy after oral intake of sumatriptan. Methods: Case presentation. Results: One patient showed typical findings on fundoscopic examination and optical coherence tomography consistent with paracentral acute middle maculopathy following oral intake of sumatriptan. Conclusion: Sumatriptan may be a trigger for paracentral acute middle maculopathy.